- Award presented at Coalition's Annual Meeting
FREMONT, Calif., Sept. 8 /PRNewswire-FirstCall/ -- Vermillion, Inc. (Nasdaq: VRML), a molecular diagnostics company, announced today that a team of scientists at Stanford University and Vermillion has been awarded the prestigious "Best Research Award" at the Annual General Meeting of the PAD Coalition. Led by Dr. John Cooke at Stanford University and Dr. Eric T. Fung, Chief Scientific Officer at Vermillion, Inc., the research team discovered a novel set of biomarkers for PAD using SELDI-TOF proteomic profiling.
"It is an honor to receive this award in recognition of our research," said Dr. John Cooke. "PAD is a serious disease that often goes undiagnosed and untreated. "A blood test that identifies people at risk for this debilitating condition could improve diagnosis and give these people a better chance of getting the life- and limb-saving therapy they need."
The PAD Coalition is a non-profit alliance of 75 leading health organizations, health professional societies, and government agencies including the National Institute of Health that have united in the goal of reducing the morbidity and mortality associated with Peripheral Artery Disease.
Vermillion has entered into an exclusive license agreement with Stanford to develop and commercialize the PAD biomarker panel. The Company plans to make the biomarker panel available in immunoassay format which will assist in making the test widely available.
About Peripheral Artery Disease (PAD)
PAD, a serious but often asymptomatic disorder affecting some eight to
12 million Americans, is caused by the buildup of fat and cholesterol, or
plaque, in the peripheral arteries, disrupting normal blood fl
|SOURCE Vermillion, Inc.|
Copyright©2008 PR Newswire.
All rights reserved